Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm talimogene laherparepvec biomarker study in unresectable melanoma
NL-OMON43786Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2016
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of talimogene laherparepvec in melanoma, sponsored by Amgen. Primary endpoint: Correlation between baseline intratumoral CD8+ cell density and objective response rate. Started Jun 2016; status: active, not recruiting.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON43786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43786.